Gabapentin is NOT indicated for bipolar depression
Gabapentin should not be used for the treatment of bipolar depression. Controlled studies in adults have definitively shown that gabapentin is not helpful for bipolar disorder 1. The FDA-approved indications for gabapentin are limited to postherpetic neuralgia and adjunctive therapy for partial onset seizures—bipolar disorder is not among them 2.
Evidence Against Use
Guideline Recommendations
The American Academy of Child and Adolescent Psychiatry practice parameters explicitly state that controlled studies in adults have not found gabapentin to be helpful for bipolar disorder 1. The guidelines emphasize that treatment should begin with FDA-approved agents for bipolar disorder in adults, which include:
For bipolar depression specifically:
- Olanzapine-fluoxetine combination (FDA-approved)
- Lamotrigine (for maintenance)
- Quetiapine (evidence in adults)
Gabapentin is notably absent from this list 1.
Controlled Trial Evidence
The highest quality evidence comes from a placebo-controlled trial that found gabapentin ineffective as adjunctive therapy in bipolar disorder 3. Remarkably, the placebo group actually showed significantly greater improvement in mania scores (decrease of 9 points) compared to the gabapentin group (decrease of 6 points, p<0.05). This negative finding is particularly damning as it suggests gabapentin may actually be inferior to placebo.
A 2021 systematic review synthesizing all available evidence concluded that gabapentin and pregabalin do not have significant clinical efficacy as either monotherapy or adjunctive therapy for bipolar disorder 4. The review noted that studies were limited by small sample sizes, heterogeneous designs, and high risk of bias.
Mechanistic Evidence
Research demonstrates that gabapentin fails to affect the arachidonic acid cascade in rat brain—a pathway that is upregulated in bipolar disorder and downregulated by effective mood stabilizers 5. This provides biological plausibility for gabapentin's clinical inefficacy.
Important Caveats
While one small open-label study (n=22) suggested potential benefit for mild to moderate bipolar depression when used adjunctively 6, this finding:
- Was not replicated in controlled trials
- Involved only adjunctive use (not monotherapy)
- Showed response primarily in patients with baseline HDRS <35
- Lacks the rigor needed to support clinical use
The FDA label for gabapentin includes warnings about increased suicidal thoughts and behavior with antiepileptic drugs 2, which is particularly concerning in bipolar depression where suicide risk is already elevated.
Clinical Bottom Line
Use evidence-based treatments for bipolar depression:
- First-line: Quetiapine, lurasidone, olanzapine-fluoxetine combination, lamotrigine
- Adjunctive: Lithium or valproate plus antidepressants (with caution for mood destabilization)
Gabapentin has no role in treating bipolar depression based on controlled trial evidence and should be avoided for this indication 1, 3.